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Investigating Real-World Clopidogrel
Pharmacogenetics in Stroke Using a
Bioresource Linked to Electronic Medical
Records
Aleksi Tornio1, Rob Flynn2, Steve Morant2, Elena Velten2, Colin N. A. Palmer1,
Thomas M. MacDonald2 and Alex S. F. Doney2
Clopidogrel efficacy is influenced by genetic variation of cytochrome P450 (CYP)2C19, however, few studies have
considered patients who have a stroke. We used electronic medical records (EMRs) linked to a bioresource to examine real-
world implications of clopidogrel pharmacogenetics in stroke. Patients hospitalized for any arterial thrombo-occlusive (ATO)
event who subsequently redeemed clopidogrel prescriptions in the community were entered into the study (n5 651). Dur-
ing 24-month follow-up, the primary endpoint of recurrent ATO or death occurred in 299 patients (46%). CYP2C19*2 loss-
of-function allele carriers had an increased risk (hazard ratio (HR)5 1.29; 95% confidence interval (CI)5 1.04–1.59;
P5 0.019). In the ischemic stroke subgroup (n5 94), the estimate of risk was greater (HR5 2.23; 95% CI5 1.17–4.24;
P5 0.015), which was further supported by ameta-analysis of available studies. In conclusion, we have demonstrated the
clinical impact of CYP2C19*2 on clopidogrel efficacy using a purely EMR approach. This suggests that the risk in the ische-
mic stroke populationmay be particularly high.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE
TOPIC?
 The loss-of-function variants of CYP2C19 are known to
impair the bioactivation and therapeutic efﬁcacy of clopidogrel.
However, no studies have considered patients who have ische-
mic strokes treated with clopidogrel monotherapy in white
populations.
WHAT QUESTION DID THIS STUDY ADDRESS?
 We set out to develop and test a model to investigate the
association of CYP2C19*2 genotype and clinical outcomes in
clopidogrel-treated individuals using EMR linkage alone. Using
this model, we investigated the risk associated with CYP2C19*2
speciﬁcally in a subgroup of patients who have an ischemic
stroke.
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE
 We demonstrated that it is possible to detect an association
between CYP2C19 genotype and clopidogrel efﬁcacy in a real-
world setting using purely observational data. Furthermore, the
risk associated with CYP2C19*2 seemed to be greater in the
ischemic stroke population largely prescribed clopidogrel
monotherapy.
HOW THIS MIGHT CHANGE CLINICAL PHARMA-
COLOGY OR TRANSLATIONAL SCIENCE
 Similar methods could be used to investigate the pharmaco-
genetics of other antiplatelet or antithrombotic drugs in biore-
sources linked to EMRs. Pharmacogenetic-guided antiplatelet
therapy should be considered in patients who have an ischemic
stroke.
Recurrent arterial thrombo-occlusive (ATO) events are a major
cause of disability and death in economically developed nations.
Antiplatelet drugs can reduce the risk of recurrence.1 Clopidogrel
is an antiplatelet prodrug with a broad clinical evidence-base and is
widely prescribed. Its active metabolite binds irreversibly to platelet
adenosine diphosphate P2Y12 receptors inhibiting platelet aggrega-
tion. The activation of clopidogrel is a two-step process catalyzed
by several cytochrome P450 (CYP) enzymes with CYP2C19 play-
ing the most important role in vivo.2–4 In European populations,
much of the variability in clopidogrel active metabolite formation
can be explained by a single genetic variant, designated CYP2C19*2
(c.681G>A, rs4244285).5 This is a loss-of-function allele that
results in an inactive form of the CYP2C19 enzyme and
impaired clopidogrel bioactivation.6 About 25% of the white
population carry this variant and when these individuals are
treated with clopidogrel they are at greater potential risk of
ATO.7–9 Because of this, the US Food and Drug Administration
issued a boxed warning in 2010 recommending “that healthcare
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professionals consider use of other antiplatelet medications or
alternative dosing strategies for patients identiﬁed as poor metab-
olizers.” In spite of this recommendation, patients who are
treated with clopidogrel largely do not get tested for their geneti-
cally determined metabolizer status and, thus, CYP2C19 poor
metabolizers do not have their antiplatelet therapy adjusted.
Most of the data about the clinical impact of clopidogrel phar-
macogenetics is derived from patients with coronary artery dis-
ease in whom dual antiplatelet therapy, usually comprising
aspirin and clopidogrel, has been the norm. However, clopidogrel
monotherapy is recommended as ﬁrst-line therapy for secondary
prevention for patients with noncardioembolic ischemic stroke
in the United Kingdom.10,11 Patients with ischemic stroke
treated with clopidogrel monotherapy may, therefore, be more
susceptible to the impact of genetically determined clopidogrel
poor metabolizer status. The American Heart Association guide-
lines for stroke from 2014 indicate the option for the use of clo-
pidogrel and aspirin only during the ﬁrst 21 days after minor
stroke or transient ischemic attack (TIA).12 Very recently, a
meta-analysis of large studies from China, including clopidogrel-
treated patients with stroke or TIA, indicated increased risk of
recurrent stroke and vascular endpoints for the carriers of
CYP2C19 loss-of-function allele.13 However, few European stud-
ies have directly considered the impact of genetic variation on
outcomes speciﬁcally in a stroke population treated with clopi-
dogrel monotherapy, and thus genotype-based dosing guidelines
for coronary artery disease cannot be directly applied to patients
who have a stroke.5,14–16
Bioresources linked to electronic medical records (EMRs) are
potentially powerful and ﬂexible platforms for exploring the real-
world potential of genomics for patient stratiﬁcation to improve
the efﬁcacy of drugs. However, models need to be developed to
make the best use of data collected for routine clinical practice.
Our objective was to use a purely record linkage approach in the
Genetics of Diabetes Audit and Research Tayside Study (GoD-
ARTS) to optimally detect the risk of recurrent ATO in
clopidogrel-treated individuals who had been Mendelian-
randomized to possession of the CYP2C19*2 allele compared to
those not possessing this variant. We subsequently determined
the risk in an ischemic stroke subgroup of patients.
RESULTS
Clopidogrel prescribed for secondary prevention of ATO
2,496 subjects participating in GoDARTS had genotype informa-
tion for CYP2C19*2 available and a record of having redeemed
at least one prescription for clopidogrel in a community phar-
macy. There were 1,657 individuals who redeemed at least one
prescription for clopidogrel following hospitalization for ATO
(myocardial infarction, ischemic stroke, or peripheral artery dis-
ease). Restricting inclusion of patients to those who redeemed
the prescription within the ﬁrst 21 days from the date of hospi-
talization resulted in a ﬁnal study population of 651 individuals.
Of these, the qualifying ATO to be included in the analysis was
myocardial infarction for 555 individuals (85%) and ischemic
stroke for 91 individuals (14%). For 2 individuals, the qualifying
event was peripheral artery disease, and 3 individuals had experi-
enced both myocardial infarction and stroke. The allele frequency
of CYP2C19*2 was 14.3% and the observed genotype frequencies
were consistent with Hardy-Weinberg equilibrium. In the group
that possessed no loss-of-function alleles (CYP2C19*1/*1; n 5
477), 209 (44%) had a recurrent ATO or death during the subse-
quent 24-month follow-up period from the date of the ﬁrst clopi-
dogrel prescription. In the group that possessed at least one loss-
of-function allele (CYP2C19*1/*2 or *2/*2 genotype; n 5 174),
there were 90 (52%) recurrent events (Table 1). This gave an
unadjusted incidence rate ratio of 1.36 (P 5 0.017) with the
population attributable risk for being a CYP2C19 loss-of-
function allele carrier of about 8%. A Cox regression additive
model for CYP2C19 genotype adjusted for age at study entry,
sex, exposure at baseline to aspirin, and/or proton pump inhibi-
tors, found an increased risk of CYP2C19*2 allele carrier status
with a hazard ratio (HR) of 1.29 (95% conﬁdence interval
(CI) 5 1.04–1.59; P 5 0.019; Table 2). A Kaplan-Meier plot of
time to ﬁrst event is shown in Figure 1a. The results remained
just signiﬁcant when limiting the study population to those whose
qualifying event was myocardial infarction only (HR5 1.25; 95%
CI5 1.00–1.57; P5 0.049).
Clopidogrel-treated ischemic stroke subpopulation
435 members of the study cohort had experienced an ischemic
stroke prior to the ﬁrst prescription of clopidogrel. However,
Table 1 Characteristics of the full study population and the ischemic stroke subpopulation by genotype and recurrent events (all
thrombo-occlusive events and death)
Mean age, years Male sex (%)
Total years of follow-up
(no. of individuals) No. of events
Yearly incidence
rate
Full population
CYP2C19*1/*1 70 301 (63) 560 (477) 209 0.37
CYP2C19*1/*2 or *2/*2 71 114 (66) 178 (174) 90 0.51
Total 70 415 (64) 737 (651) 299 0.41
Ischemic stroke subpopulation
CYP2C19*1/*1 74 42 (63) 93.1 (67) 17 0.18
CYP2C19*1/*2 or *2/*2 76 16 (59) 29.4 (27) 11 0.37
Total 74 58 (62) 122 (94) 28 0.23
ARTICLES
282 VOLUME 103 NUMBER 2 | FEBRUARY 2018 | www.cpt-journal.com
again restricting inclusion of patients to those redeeming a ﬁrst
prescription for clopidogrel in the community within the ﬁrst
21 days after the date of hospitalization resulted in a study popu-
lation of 94 individuals (including the three individuals who had
a record of both ischemic stroke and myocardial infarction
within 21 days). The allele frequency of CYP2C19*2 in this
smaller group was 16.0% and the genotype frequencies were con-
sistent with Hardy-Weinberg equilibrium. In this population, we
found a higher estimation of risk by CYP2C19 genotype (Table 1,
Figure 1b) compared to the full study population. In a Cox
regression model, which included the same covariates as the full
population, the HR was 2.23 (95% CI 5 1.17–4.24; P 5 0.015;
Table 2). Only 10 of these individuals were prescribed aspirin
concomitantly.
DISCUSSION
We have performed a real-world study using purely EMR linkage
of routine administrative clinical data in GoDARTS in the Tay-
side region of Scotland. We have demonstrated the feasibility of
investigating the clinical impact of Mendelian-randomization to
possession of the CYP2C19*2 loss-of-function allele in patients
redeeming prescriptions for clopidogrel following hospitalization
for an ATO. Although we have only considered a single loss-of-
function allele, this study further underscores the uncomfortable
implication that at least one in every four patients who are pre-
scribed clopidogrel will receive signiﬁcantly reduced beneﬁt due
to their genotype and remain at higher risk of future ATOs. It
also suggests that patients with ischemic stroke who subsequently
receive clopidogrel monotherapy, which due to current guidelines
is largely the case in the United Kingdom, where this study was
undertaken, may be even more exposed to further acute events
compared with patients with myocardial infarction who usually
receive dual antiplatelet therapy. Given that the recent trial for
use of ticagrelor in acute ischemic stroke17 has not been encour-
aging, it is likely that these guidelines will remain unchanged in
the foreseeable future. Interestingly, however, in the PLATO
genetic substudy, ticagrelor was not, in fact, signiﬁcantly better
than clopidogrel in the group with no CYP2C19 loss-of-function
alleles.9
By demonstrating the clinical impact of a well-established
pharmacogenetic paradigm in a bioresource linked to extensive
EMRs using a purely record linkage approach, this study indicates
the general utility of such resources to investigate real-world clini-
cal implications of genetic variability inﬂuencing drug efﬁcacy
and safety across a wide array of clinical situations.18 Indeed, we
have demonstrated this previously in GoDARTS in the context
of efﬁcacy and side effects of statins.19,20 To the best of our
knowledge, the only two other studies that have used a biore-
source linked to EMRs to investigate CYP2C19 genotype in the
context of clopidogrel therapy also utilized manual review of elec-
tronically deﬁned recurrent cardiovascular events.21,22 Our HR is
lower than that estimated in the study by Delaney et al.,21
although the use of a case-control methodology in that study
meant that a population-based HR was not possible to be deter-
mined and, therefore, cannot be directly compared with our data.
Table 2 The full Cox regression model for the endpoint of any
thrombo-occlusive event or death in the full study population
and the ischemic stroke subpopulation
HR 95% CI P value
Full population
CYP2C19, additive 1.29 1.04–1.59 0.019
Age, years 1.01 1.00–1.02 0.206
Male sex 0.93 0.74–1.18 0.561
Aspirin use 0.92 0.73–1.16 0.483
PPI use 1.02 0.77–1.36 0.887
Ischemic stroke subpopulation
CYP2C19, additive 2.23 1.17–4.24 0.015
Age, years 1.01 0.97–1.05 0.653
Male sex 0.66 0.30–1.43 0.287
Aspirin use 0.25 0.03–1.95 0.186
PPI use 2.12 0.83–5.38 0.114
CI, confidence interval; HR, hazard ratio; PPI, proton pump inhibitor.
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Figure 1 Kaplan-Meier curves of all arterial thrombo-occlusive events and
death for (a) the whole clopidogrel-treated population and (b) the ischemic
stroke subpopulation.
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As we had access to hospital admission records and a prescription
dataset, which includes all community-dispensed prescriptions,
we could reliably identify patients who were hospitalized due to
an acute ATO and were subsequently initiated on clopidogrel
using a straightforward model. As such, our approach could be
applied to test other hypotheses, such as pharmacogenetics of
other antiplatelet drugs.
In 2010, UK guidelines for the secondary prevention of stroke
were updated to recommend clopidogrel monotherapy and, prior
to, that most ischemic strokes would have been treated with a
combination of aspirin and dipyridamole meaning that our sub-
study was relatively small but comprised patients treated predom-
inantly with clopidogrel monotherapy.10 When comparing our
results with previous studies, it should be noted that there are dif-
ferences in treatment practices between countries and guide-
lines.12,23 Initial dual antiplatelet therapy with aspirin and
clopidogrel is recommended in some cases of, for example, intra-
cranial stenosis. Also, dual antiplatelet therapy is suggested for
initiation within 24 hours of a minor ischemic stroke or TIA
and for continuation for 21 days in the American Heart Associa-
tion guidelines.12
A recent meta-analysis of studies, including 4,762 clopidogrel-
treated patients with stroke or TIA, indicated an increased risk
for recurrent stroke in CYP2C19 loss-of-function allele carriers.13
The overall estimate of the risk ratio for composite vascular
events was 1.51 (95% CI 5 1.10–2.06), which is very similar to
results obtained in the two meta-analyses of studies in patients
with coronary artery disease with HRs of 1.57 (95% CI 5 1.13–
2.16) and 1.50 (95% CI 5 1.21–1.87).7,8 It is noteworthy that
the stroke meta-analysis included patients with various states of
cerebrovascular disease, and more than half of the patients were
treated with dual antiplatelet therapy. Most of the patients
included in the analysis were Chinese and only 386 patients (8%
of the total 4,762) were of white origin and of these over 90%
were from two studies using dual antiplatelet therapy.22,24 Inter-
estingly, the risk of vascular endpoints in relation to CYP2C19
genotype seems to be lower in studies in which the study protocol
clearly included dual antiplatelet therapy for 90 days or longer
than in studies using clopidogrel monotherapy.13 Indeed, exclud-
ing the small number of individuals who were co-prescribed aspi-
rin in our study further increased the HR (data not shown). A
meta-analysis of our study with the one study clearly including
patients solely on clopidogrel monotherapy, which had a very
similar point estimate of risk compared to our study, provides an
overall estimate of the HR for CYP2C19 loss-of-function allele
carriers of 2.28 (95% CI 5 1.53–3.40; P 5 0.00005; Figure 2).
Notably, this point estimate is higher than the upper 95% CI
limits in the meta-analyses of patients with coronary artery dis-
ease.7,8 These ﬁndings suggest that patients who have ischemic
strokes treated with clopidogrel monotherapy may be at greater
risk based on their CYP2C19 genotype than patients treated
with dual antiplatelet therapy regardless of indication. It is bio-
logically plausible that individuals on clopidogrel monotherapy in
whom its bioactivation is impaired are especially vulnerable to
recurrent events, whereas the use of aspirin concomitantly could
diminish the CYP2C19 genotype effect. These results underline
the fact that the implications of CYP2C19 genotype should not
be directly extrapolated to different disease states or treatment
strategies (e.g. clopidogrel monotherapy vs. dual antiplatelet
therapy).
One limitation of our study is that we investigated the effect of
only a single CYP2C19 variant. Other CYP2C19 loss-of-
function alleles have been described, but their minor allele fre-
quencies are low in white populations, making their relevance
limited for the current study. On the other hand, CYP2C19*17
allele has been associated with enhanced clopidogrel response and
increased risk of bleeding in some studies.25–28 Variants in other
genes, including ABCB1, CES1, and PON1, have been suggested
to play a role in the interindividual variability of clopidogrel
response, but these results have not been widely replicated.27,29,30
A further weakness is that we were unable to include data in rela-
tion to medical or other treatments during the time period in the
hospital with information on treatment coming entirely from
redemption of prescriptions from community pharmacies. This
was the principal reason for requiring undertaking the sensitivity
analysis for optimizing the time between hospital admission and
the ﬁrst community-redeemed clopidogrel prescription. Finally,
due to the limited sample size and limitations of the EMR data,
we could not include all environmental or genetic factors that
could inﬂuence clopidogrel response.31–33 However, it is unlikely
that these factors would be differently distributed between the
CYP2C19 genotype groups, as there is no evidence linking
CYP2C19 with any diseases or conditions independent of drug
metabolism and response, and, thus, they are not likely to intro-
duce bias to our analysis.5
In conclusion, we have shown that using purely observational
routinely collected healthcare data and record linkage methodol-
ogy, it is possible to demonstrate the real-world impact of
CYP2C19 genotype on clopidogrel efﬁcacy. Approximately one
quarter of patients with ischemic stroke or TIA who are treated
with clopidogrel remain at signiﬁcantly greater risk of future
events because of their CYP2C19 genotype. There are potentially
several alternative treatments available for such individuals,
including increasing the dose of clopidogrel, however, one of the
major impediments to clinically identifying them is the lack of
evidence for clinical effectiveness of speciﬁcally genotyping all
Overall
Our study
Sun et al
Study
2.28 (1.53, 3.40)
2.23 (1.17, 4.24)
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Figure 2 Meta-analysis of our study with the study by Sun et al.16 HR,
hazard ratio; CI, confidence interval.
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patients to identify this subgroup. With the growing number of
individuals now taking part in large biorepositories linked to de-
identiﬁed patient EMR data, there is an ideal opportunity and
arguably an ethical imperative to perform such studies by linking
pre-existing genotypes in these bioresources directly to hospital
systems so that genotype data can be used to alter therapy
appropriately.
METHODS
Source population
The GoDARTS is a large TENOVUS and Wellcome Trust funded
study derived from the Tayside region of Scotland for investigating
genetic determinants of type 2 diabetes, response to therapy, and its com-
plications. GoDARTS comprises approximately 10,500 patients with
type 2 diabetes and 7,500 individuals with a similar demographic but
with no diagnosis of type 2 diabetes at recruitment. Recruitment into
GoDARTS commenced in 1997 and was complete in 2007 and, there-
fore, individuals can have up to 19 years of follow-up. All individuals
provided a blood sample for DNA extraction and genotyping as well as
consent for linkage of this information to detailed longitudinal EMRs
that are available through an established regional clinical health infor-
matics research infrastructure. Genotyping for CYP2C19*2 had taken
place previously as component of genetic studies in the GoDARTS bio-
resource. There were 15,317 subjects who had genotype information
available for the CYP2C19*2 polymorphism. Of these, 11,346 (74.1%)
were noncarriers of the CYP2C19*2 allele and were designated as
CYP2C19*1/*1, 3,656 (23.9%) had the CYP2C19*1/*2 genotype, and
315 (2.1%) had the CYP2C19*2/*2 genotype (CYP2C19*2 allele fre-
quency 5 0.14). GoDARTS was approved by the Tayside Medical
Ethics Committee. Informed consent was obtained from all participants.
Clinical datasets used
The main clinical datasets used for this study were the Tayside prescrib-
ing dataset, originally developed through the Medicines Monitoring
Unit (MEMO) at the University of Dundee, which contains a longitudi-
nal record of all prescriptions dispensed by community pharmacies; the
Scottish Morbidity Records (SMR01), which contains all hospital dis-
charge diagnoses coded as International Classiﬁcation of Disease (ICD)-
9 and ICD-10, and General Register Ofﬁce (GRO) information
containing date and cause of death (also ICD coded). These data are
provided in anonymized form through the Health Informatics Centre at
the University of Dundee and linked to genetic data assimilated by the
Centre for Pharmacogenomics.
Study population
The study population comprised individuals in GoDARTS who had
been genotyped for CYP2C19*2 polymorphism and who had also
redeemed at least one prescription for clopidogrel. As our study relied
upon hospital admission data for ATO but community redemption of
medicines following hospital discharge, this meant that there was a time
period between the date of qualifying event (date of hospital admission)
and the date of the ﬁrst knowledge of exposure to clopidogrel. It is estab-
lished that the majority of recurrent ATO occur rapidly within the ﬁrst
few weeks of the index event. Therefore, we undertook a sensitivity anal-
ysis to determine the optimum time difference between the date of hos-
pital admission for the index event and the ﬁrst community encashment
of clopidogrel for inclusion in the analysis. This balanced larger numbers
of individuals for inclusion who had been in the hospital longer with
potentially more severe disease and greater treatment intensity against
smaller numbers of patients who were more ambulatory with lower treat-
ment intensities and earlier risk. To ensure the population had active dis-
ease, the sensitivity analysis resulted in an optimum time between
hospital admission and prescription encashment to be no greater than
21 days (3 weeks) following a hospital admission for any ATO (myocar-
dial infarction, ischemic stroke, or peripheral artery disease) derived from
the ICD codes on hospital admission. A substudy of this population was
restricted to those individuals whose qualifying ischemic event had been
an ischemic stroke.
Statistical analysis
Cox’s proportional hazards model was used to compare the rate of end-
points between individuals carrying one or two CYP2C19*2 alleles and
noncarriers of CYP2C19*2 during exposure to clopidogrel. Because of
the limitations of using purely observational data available through medi-
cal record linkage, we considered the study population to have become at
risk due to the presence of the CYP2C19*2 allele after community
encashment of their ﬁrst clopidogrel prescription. Subjects were followed
until the primary endpoint, which was either a hospitalization for a fur-
ther ATO or their death from any cause. Censoring was at 24 months
(96 weeks), or when no further data was available in the record (i.e., the
subject had left the Tayside area or the end of study date occurred, which
was 14 February 2016). Exposure to clopidogrel was modeled based on
the ﬁrst community-redeemed prescription and we did not censor for
apparent further changes in clopidogrel prescribing, as it would have
been impossible to know whether the events occurred on or off treat-
ment. We also included in the model exposure to aspirin and proton
pump inhibitors because both of these may inﬂuence outcome. Due to
the relatively small numbers available, we simply modeled exposure to
any proton pump inhibitor. All analyses were adjusted for age at becom-
ing at risk (ﬁrst dispensed clopidogrel prescription) and gender. STATA
version 11.2 (StataCorp LP, College Station, TX) was used for all
analyses.
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